B-Cell and T-Cell Combined Disorders Clinical Presentation

  • Author: Terry W Chin, MD, PhD; Chief Editor: Harumi Jyonouchi, MD  more...
 
Updated: Aug 26, 2014
 

History

Clinical manifestations of many combined B-cell and T-cell deficiencies derive from associated organ involvement, thus eliciting variable onsets for the different symptoms. Neurologic and cutaneous symptoms predominate in ataxia-telangiectasia (AT) and Nijmegen breakage syndrome (NBS). Autoimmune endocrinopathies and cutaneous manifestations are seen in patients with chronic mucocutaneous candidiasis (CMC) and immune dysregulation with polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. In other combined B-cell and T-cell deficiencies, the presence of unusual organisms in certain infections, the chronic nature of infectious processes, and autoimmune phenomena may indicate the presence of an underlying immunodeficiency.

AT is an obvious diagnosis when both ataxia and telangiectasia are present. A diagnosis of AT can also be made upon onset of ataxia and before telangiectasia appears, if confirmed by laboratory test results. In most patients, a misdiagnosis of cerebral palsy is usually made because ataxia most often occurs during infancy. Telangiectasia usually does not appear until patients are aged 5 years.

In a review of 48 patients with AT, mean age of ataxia onset was 15 months; mean age of telangiectasia onset was 72 months.[6] This study by confirmed that a misdiagnosis of cerebral palsy was made in most patients (29 of 48). To alleviate this problem, the study recommends routine serum alpha-fetoprotein (AFP) testing for all children with persistent ataxia.

Ataxia is initially cerebellar, with associated posture and gait problems. Speech may become slurred. Movement disorders also occur and may be choreoathetoid or ticlike. Oculomotor apraxia is usually present, and, less often, a dysconjugate gaze is noted. Muscle weakness may appear late in the course, with subsequent muscle atrophy. Mental function can be affected.

AT has increased alpha fetoprotein levels, whereas NBS has microcephaly and mental retardation.

Telangiectasia usually occurs on the bulbar conjunctivae in patients younger than 5-6 years and becomes more prominent in other areas, especially the pinna. Other cutaneous manifestations include progressive cutaneous atrophy, areas of hypopigmentation or hyperpigmentation, hypertrichosis, atopic dermatitis, and cutaneous malignancies. See the images below.

Telangiectasia. Telangiectasia.
Telangiectasia of conjunctivae. Telangiectasia of conjunctivae.

Bloom syndrome may also have telangiectasias, especially sun-exposed areas. However, patients have short stature and birdlike facies.

All patients have a deficiency of cell-mediated immunity. However, deficiency in humoral immunity is more variable. Therefore, the resulting predisposition to infection can vary. Recurrent sinopulmonary infections may be a complaint before ataxia or telangiectasia develops. An increase in lower respiratory tract infections is observed with age with subsequent chronic lung disease. Impaired oropharyngeal swallowing mechanisms may contribute with chronic aspiration. Infections can be caused by viral and bacterial pathogens, although typically not by opportunistic agents.

In a review of 100 patients with AT, recurrent upper and lower tract infections were common, including otitis media in 46%, sinusitis in 27%, bronchitis in 19%, and pneumonia in 15%. Systemic bacterial and severe viral or opportunistic infections were uncommon.

Although endocrine abnormalities are uncommon, they may include failure to develop secondary sex characteristics. Stiehm states that no offspring of AT homozygotes are known.[3] Patients may also have growth failure.

Patients with CMC have persistent or recurrent candidal infections of the skin, nails, and mucous membranes. The extent and location of infections, genetic factors, and associated autoimmune disorders delineate 6 clinical syndromes.

Candidiasis is almost always observed in patients with CMC. Infants with CMC type 3 usually present with persistent diaper rash or other localized lesions involving the extremities. Extreme hyperkeratosis may occur. Persistent or recurrent thrush is also common. Consider CMC in patients when chronic oral candidiasis (CMC type 1) continues after cessation of antibiotics or inhaled corticosteroid therapy and when T-cell deficiency has been excluded. Esophageal or tracheal candidiasis is uncommon and may simply represent colonization of mucous membranes after a course of systemic antibiotic therapy. See the image below.

A 5-year-old boy with thrush. A 5-year-old boy with thrush.

More extensive cutaneous infections with skin, nail, and mucous membrane involvement may develop in late childhood or during adolescence (CMC type 4). These patients apparently are less likely to develop endocrinopathies.

According to Stiehm, "It is important to appreciate that the endocrinopathies may develop any time from childhood through adulthood and that patients may have sequential loss of functions of various endocrine organs..."[3] According to one study, the most commonly affected organs are the parathyroid glands (54 of 68 patients), adrenal glands (49 of 68 patients), and thyroid gland (2 of 68 patients). Gonadal failure commonly causes infertility. Insulin-dependent diabetes occurs in approximately 10% of patients. Overall, CMC is associated with autoimmune endocrinopathies in about 40% of patients.

An association of CMC with thymomas (CMC type 5) has been described, usually in adult or middle-aged patients. These patients may also have other autoimmune disorders, such as myasthenia gravis, aplastic anemia, and hypogammaglobulinemia.

An association of chronic keratitis with CMC has been noted and appears to be an autosomal dominant trait.

Patients with CMC are susceptible to frequent infections by viruses and bacteria in the skin and in the upper and lower respiratory tracts.

Other autoimmune disorders are common and include various autoimmune hematologic disorders (eg, red blood cell [RBC], white blood cell [WBC], platelets), chronic active hepatitis, and juvenile rheumatoid arthritis for CMC.

The combination of dermatitis and thrombocytopenia (as an autoimmune process) in males may confuse IPEX with patients with Wiskott-Aldrich syndrome. Indeed, IPEX was originally thought to be a Wiskott-Aldrich syndrome variant because the gene that encodes WASP also lies in the same region as FOXP3 gene. The dermatitis in IPEX is also eczematous in nature.

Enteropathy with failure to thrive is almost always present in IPEX. It usually presents with watery diarrhea and villous atrophy is commonly found on intestinal biopsy.

Endocrinopathy is commonly present but may not appear initially. The most common endocrine dysfunction is early onset insulin-dependent diabetes mellitus. Thyroid disease (either hypothyroidism or hyperthyroidism) is also common.

Examples of autoimmune phenomena include immune hemolytic anemia, immune thrombocytopenia, autoimmune neutropenia, lymphadenopathy, splenomegaly, tubular nephropathy, or alopecia.

Patients with IPEX usually present in early infancy and may die within the first 2 years of life due to either metabolic derangements or sepsis. The most common pathogens were Staphylococcus, cytomegalovirus (CMV), and Candida.

Neoplastic diseases other than thymomas can occur, which emphasizes the importance of T cells in immune surveillance. However, a greater incidence of malignancy is observed in AT, especially lymphoid tumors, which has been attributed to their increased sensitivity to radiation. Occasionally, leukemia has been a presenting finding of AT. On the other hand, CMC with squamous cell carcinoma of the oral cavity or esophagus has also been described.[7]

Next

Physical

Depending on the specific combined immunodeficiency syndromes, physical examination may yield varying signs, as follows:

In patients with AT, gait abnormalities occur at a median age of 15 months. Deterioration of the newly acquired developmental milestone of walking signals a problem.

All patients manifest progressive cerebellar ataxia. However, the classic form has onset in infancy, and steady progression to milder forms in which the progression may be slower or the onset may be later have been noted. Other neurologic signs include dystonia and oculomotor apraxia. Drooling, strabismus, and a masklike facies may be seen. In addition to cerebellar signs, extrapyramidal and posterior column signs may be present. Reflexes are decreased, and muscle weakness may be present. Sensory involvement is uncommon.

Telangiectasia is commonly observed on the bulbar conjunctivae and may occur in children aged 1-6 years. Other areas, such as the lateral aspect of the nose, the ears, the antecubital and popliteal areas, and the dorsa of the hands and feet, may be affected later.

In CMC, almost all patients have skin or nail findings.[8] Mucous membranes in the oral cavity may be covered with a patchy pseudomembrane composed of mycelial Candida albicans (ie, thrush). Infants may have a persistent diaper rash with fungal infection. In more extensive forms, nails and extremities may develop severe hyperkeratosis with nail deformities.

In IPEX, the typical rash is eczematoid.

Previous
Next

Causes

The gene responsible for AT, designated ATM (ie, AT, mutated), encodes for a protein that belongs to a family of phosphatidylinositol 3-kinase (PI3-K)–related kinases (PIKK). Members of this family are involved in mitogenic signal transduction, intracellular protein transport, and control of the cell cycle. In biologic terms, cells have an extreme sensitivity to radiation and an increased predisposition to become cancerous.

ATM is located on the long arm of chromosome 11 at subband q22.3. ATM is a large gene, with over 300 mutations described in 66 exons and no common, predominant mutation.

In contrast, the NBS1 gene involved in NBS is located on chromosomal band 8q21. Seven mutations are reported worldwide, with a high predominance of the founder mutation 567del5 in the Slavonic population.

Most patients with the classic AT phenotype are homozygous or compound heterozygous for ATM mutations that result in a truncated or unstable protein with total loss of ATM function. Some patients have mild forms of the disease, termed AT variants, and are either homozygous for mild mutations or compound heterozygotes for mild mutations. These mutations are leaky splice or missense mutations. Preservation of neurologic function is correlated with the degree of ATM protein kinase activity. About 10% of normal ATM kinase activity is apparently adequate to moderate the phenotype but not to prevent it.

The additional recognition of many ATM substrates involved in the recognition and repair of DNA double-strand breaks may also allow for the heterologous symptoms among patients with AT, some of whom may not have symptoms until adulthood.

Mutations in the ATM gene are probably not a common cause for cerebellar ataxia other than AT.

With the aid of molecular testing, AT can be distinguished from other autosomal recessive cerebellar ataxias, such as Friedrich ataxia, Mre11 deficiency (AT-like disease), and the oculomotor apraxias 1 (aprataxin deficiency) and 2 (senataxin deficiency). In addition, NBS1 deficiency defines NBS syndrome, and helicase gene defect defines Bloom syndrome.

Heterogeneous manifestations of CMC may indicate numerous causes and a heterogeneous pattern of inheritance.

Immunological studies indicate that dendritic maturation may be impaired in both CMC and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Subsequent altered regulation of pattern recognition receptors may be responsible for the disease manifestations.[9]

Other studies show that these patients have an inability to clear Candida. This may be due to a defect in the immune response of interleukin (IL)-17-producing T cells.[10]

CMC is included as part of the APECED disorder, which is also known as autoimmune polyglandular syndrome type I (APS I). This disease has been mapped to chromosome 21q22.3, and the gene is identified as the autoimmune regulator (AIRE) gene. It appears to be involved in DNA binding. At least 60 different disease-causing mutations in AIRE have been discovered, and the role in various manifestations of CMC and APECED/APS I are under investigation. AIRE may be involved in thymocyte negative selection, which may partially account for autoimmunity.

CMC can be broadly classified into familial (inherited) or nonfamilial (noninherited) forms. Familial forms are inherited as autosomal dominant or autosomal recessive and are associated with or without varying degrees of autoimmune endocrinopathy. Therefore, determining whether the AIRE gene markers (and autoantibodies) segregate with disease in a family in whom the diagnosis of CMC is possible is important.

Two other familial subtypes include an autosomal dominant form with nail candidiasis and intercellular adhesion molecule-1 (ICAM-1) deficiency and an autosomal recessive form with hyperimmunoglobulinemia E. Chronic localized CMC has no apparent genetic component.

Previous
 
 
Contributor Information and Disclosures
Author

Terry W Chin, MD, PhD Associate Clinical Professor, Department of Pediatrics, University of California, Irvine, School of Medicine; Associate Director, Cystic Fibrosis Center, Attending Staff Physician, Department of Pediatric Pulmonology, Allergy, and Immunology, Memorial Miller Children's Hospital

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Federation for Clinical Research, American Thoracic Society, California Society of Allergy, Asthma and Immunology, California Thoracic Society, Clinical Immunology Society, Los Angeles Pediatric Society, Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Noufa Alonazi, MD, MBBS Allergy and Immunology Postdoctoral Fellow, Department of Pediatrics, Loma Linda University and Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.

Acknowledgements

John Wilson Georgitis, MD Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

References
  1. Somech R, Lev A, Grisaru-Soen G, Shiran SI, Simon AJ, Grunebaum E. Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency. Immunol Res. 2013 May. 56(1):150-4. [Medline].

  2. Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol. 2008 May. 28 Suppl 1:S11-9. [Medline].

  3. Stiehm ER. Immunologic Disorders in Infants and Children. 4th ed. WB Saunders Co; 1996.

  4. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014 Aug 20. 312(7):729-38. [Medline].

  5. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006 Aug. 91(8):2843-50. [Medline].

  6. Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998 Jul. 102(1 Pt 1):98-100. [Medline].

  7. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol. 2008 Feb. 46(1):85-91. [Medline].

  8. LeBoeuf N, Garg A, Worobec S. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Pediatr Dermatol. 2007 Sep-Oct. 24(5):529-33. [Medline].

  9. Hong M, Ryan KR, Arkwright PD, et al. Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin Exp Immunol. 2009 Apr. 156(1):40-51. [Medline]. [Full Text].

  10. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008 Nov. 128(11):2640-5. [Medline].

  11. Stray-Pedersen A, Aaberge IS, Fruh A, Abrahamsen TG. Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol. 2005 Jun. 140(3):507-16. [Medline].

  12. Pashankar F, Singhal V, Akabogu I, Gatti RA, Goldman FD. Intact T cell responses in ataxia telangiectasia. Clin Immunol. 2006 Aug. 120(2):156-62. [Medline].

  13. Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008 Nov. 93(11):4389-97. [Medline].

  14. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006 Jul. 3(7):e289. [Medline].

  15. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31. 371(5):434-46. [Medline].

  16. Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol. 2003 Feb. 90(2):259-64. [Medline].

  17. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook 2008-2009. 16th edition. Cleveland, Ohio: Lexi-Comp Inc; 2008.

  18. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008 Nov. 28(4):765-78, viii. [Medline].

  19. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005 Aug 15. 62(16 Suppl 3):S5-11. [Medline].

  20. Siegel J. The Product: All intravenous immunoglobulins are not equivalent. Pharmacother. 2005. 25(11 Pt 2):78S-84S.

  21. Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998 Jun. 101(6 Pt 1):848-9. [Medline].

  22. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006 Aug. 38(8):873-5. [Medline].

  23. Buoni S, Zannolli R, Sorrentino L, Fois A. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol. 2006 Oct. 63(10):1479-82. [Medline].

  24. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006 Jul. 91(7):610-1. [Medline].

  25. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol. 1997 Sep. 100(3):415-23. [Medline].

  26. Claret Teruel G, Giner Munoz MT, Plaza Martin AM, et al. Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12 affected patients. Pediatr Allergy Immunol. 2005 Nov. 16(7):615-8. [Medline].

  27. Hughes WT. Prevention of infections in patients with T cell defects. Clin Infect Dis. 1993 Nov. 17 Suppl 2:S368-71. [Medline].

  28. Mila J, Matamoros N, Pons de Ves J, Raga S, Iglesias Alzueta J. [The Spanish Registry of Primary Immunodeficiencies. REDIP-1998]. Sangre (Barc). 1999 Apr. 44(2):163-7. [Medline].

  29. Regueiro JR, Porras O, Lavin M. Ataxia-telangiectasia: a primary immunodeficiency revisted. Immunol Allergy Clin North Am. 2000. 20:177-206.

  30. Ruan QG, She JX. Autoimmune polyglandular syndrome type 1 and the autoimmune regulator. Clin Lab Med. 2004 Mar. 24(1):305-17. [Medline].

  31. Sadighi Akha AA, Humphrey RL, Winkelstein JA, Loeb DM, Lederman HM. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients. Medicine (Baltimore). 1999 Nov. 78(6):370-81. [Medline].

  32. Sahama I. Radiological Imaging in Ataxia Telangiectasia: a Review. Cerebellum. 2014.

  33. Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005 Jun. 39(6):537-43. [Medline].

  34. Schwartz SA. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am. 2000 Dec. 47(6):1355-69. [Medline].

  35. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005 Oct. 58(10):1009-15. [Medline].

  36. Thampakkul S, Ballow M. Replacement intravenous immunoglobulin. Serum globulin therapy in patients with antibody immune deficiency. Immunol Aller Clin North Am. 2001. 21:165.

 
Previous
Next
 
Telangiectasia.
Radiograph shows an 8-month-old boy who required ventilatory support for bilateral pneumonia and who received intravenous antibiotics. The patient recovered and returned home.
Chest radiograph in an 8-month-old boy 2 weeks after he was treated for bilateral pneumonia. The patient returned to the emergency department with a fever and breathing problems.
Chest radiograph in a 9-month-old boy. The patient developed breathing problems 1 month after recovering from a second hospitalization for pneumonia. By this time, serum immunoglobulin levels from the second hospitalization were in the patient's record and showed an immunoglobulin G level of 156 mg/dL and undetectable immunoglobulin A and immunoglobulin M levels. Subsequent bronchoscopy showed the presence of Pneumocystis carinii and cytomegalovirus.
Telangiectasia of conjunctivae.
A 5-year-old boy with thrush.
Table. Intravenous Immunoglobulin Therapy [17, 18, 19, 20]
Brand(Manufacturer) Manufacturing Process pH Additives (IVIG products containing sucrose are more often associated with renal dysfunction, acute renal failure, and osmotic nephrosis, particularly with preexisting risk factors [eg, history of renal insufficiency, diabetes mellitus, age >65 y, dehydration, sepsis, paraproteinemia, nephrotoxic drugs].) Parenteral Form and Final Concentrations IgA Content mcg/mL
Carimune NF



(ZLB Behring)



Kistler-Nitschmann fractionation, pH 4, nanofiltration 6.4-6.8 6% solution: 10% sucrose, < 20 mg NaCl/g protein Lyophilized powder 3%, 6%, 9%, 12% Trace
Flebogamma



(Grifols USA)



Cohn-Oncley fractionation, PEG precipitation, ion-exchange chromatography, pasteurization 5.1-6 Sucrose free, contains 5% D-sorbitol Liquid 5% < 50
Gammagard Liquid 10%



(Baxter Bioscience)



Cohn-Oncley cold ethanol fractionation, cation and anion exchange chromatography, solvent detergent treated, nanofiltration, low pH incubation 4.6-5.1 0.25 M glycine Ready-for-use liquid 10% 37
Gammar-P IV



(ZLB Behring)



Cohn-Oncley fraction II/III, ultrafiltration, pasteurization 6.4-7.2 5% solution: 5% sucrose, 3% albumin, 0.5% NaCl Lyophilized powder 5% < 20
Gamunex



(Talecris Biotherapeutics)



Cohn-Oncley fractionation, caprylate-chromatography purification, cloth and depth filtration, low pH incubation 4-4.5 Contains no sugar, contains glycine Liquid 10% 46
Gammaplex



(Bio Products)



Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation 4.8-5.1 Contains sorbitol (40 mg/mL); do not administer if fructose intolerant Ready-for-use solution 5% < 10
Iveegam EN



(Baxter Bioscience)



Cohn-Oncley fraction II/III, ultrafiltration, pasteurization 6.4-7.2 5% solution: 5% glucose, 0.3% NaCl Lyophilized powder 5% < 10
Polygam S/D



Gammagard S/D



(Baxter Bioscience for the American Red Cross)



Cohn-Oncley cold ethanol fractionation, followed by ultra centrafiltration and ion exchange chromatography, solvent detergent treated 6.4-7.2 5% solution: 0.3% albumin, 2.25% glycine, 2% glucose Lyophilized powder 5%, 10% < 1.6 (5% solution)
Octagam



(Octapharma USA)



9/24/10: Withdrawn from market because of unexplained reports of thromboembolic events



Cohn-Oncley fraction II/III, ultrafiltration, low pH incubation, S/D treatment pasteurization 5.1-6 10% maltose Liquid 5% 200
Panglobulin



(Swiss Red Cross for the American Red Cross)



Kistler-Nitschmann fractionation, pH 4, trace pepsin, nanofiltration 6.6 Per gram of IgG: 1.67 g sucrose, < 20 mg NaCl Lyophilized powder 3%, 6%, 9%, 12% 720
Previous
Next
 
 
 
Medscape Consult
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.